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Summary: Evidence supporting the current World Health Organization recommendations of early antiretroviral
therapy (ART) initiation for adolescents is inconclusive. We leverage a large observational data and compare, in
terms of mortality and CD4 cell count, the dynamic treatment initiation rules for HIV-infected adolescents. Our
approaches extend the marginal structural model for estimating outcome distributions under dynamic treatment
regimes (DTR), developed in Robins et al. (2008), to allow the causal comparisons of both specific regimes and
regimes along a continuum. Furthermore, we propose strategies to address three challenges posed by the complex data
set: continuous-time measurement of the treatment initiation process; sparse measurement of longitudinal outcomes
of interest, leading to incomplete data; and censoring due to dropout and death. We derive a weighting strategy for
continuous time treatment initiation; use imputation to deal with missingness caused by sparse measurements and
dropout; and define a composite outcome that incorporates both death and CD4 count as a basis for comparing
treatment regimes. Our analysis suggests that immediate ART initiation leads to lower mortality and higher median
values of the composite outcome, relative to other initiation rules.
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11. Introduction
1.1 Dynamic treatment regimes and treatment of pediatric HIV infection
HIV/AIDS continues to be one of the leading causes of burdensome disease in adolescents
(10–19 years old). Globally, an estimated 2.1 million adolescents were living with HIV in 2013,
with most living in sub-Saharan Africa (WHO, 2015). Current World Health Organization
(WHO) treatment recommendations for adolescents call for initiation of antiretroviral ther-
apy (ART) upon diagnosis with HIV (WHO, 2015). Previously, and particularly for resource-
limited settings (RLS), WHO recommendations called for delaying treatment until a clinical
benchmark signaling disease progression was reached. For example, the 2013 guidelines
recommended initiating ART when CD4 cell count – a marker of immune system function –
fell below 500.
For investigating the effectiveness of ART initiation rules, adolescents are a subpopulation
of particular interest, particularly because of issues related to drug adherence (Mark et al.,
2017). For adolescents, early initiation of ART can potentially increase the risk of poor
adherence, leading to development of drug resistance, while initiating too late increases
mortality and morbidity associated with HIV. Evidence from both clinical trials (Luzuriaga
et al., 2004; Violari et al., 2008) and observational studies (Berk et al., 2005; Schomaker
et al., 2017) supports the immediate ART initiation rule recommended by the WHO for
children under 10 years of age. Conclusive evidence is lacking for adolescents. The 2015 WHO
guidelines did not identify any study investigating the clinical outcomes of adolescent-specific
treatment initiation strategies (WHO, 2015). A recent large-scale study (Schomaker et al.,
2017) of HIV-infected children (1–9 years) and adolescents (10–16 years) found mortality
benefit associated with immediate ART initiation among children, but inconclusive results
for the adolescents, and recommended further study of this group. Evaluating ART initiation
rules specific to adolescents therefore remains important.
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Prior to 2015, WHO guidelines for treatment initiation were expressed in the form of
a dynamic treatment regime (DTR), formulated as “initiate when a specific marker crosses
threshold value q”. In a DTR, the decision to initiate treatment for an individual can depend
on evolving treatment, covariate, and marker history (Chakraborty and Murphy, 2014).
In this paper, we use observational data on 1962 HIV-infected adolescents, collected as
part of the East Africa IeDEA Consortium (Egger et al., 2012) to compare the effectiveness
of CD4-based DTR, with emphasis on comparisons to the strategy of immediate treatment
initiation. Our approach is to emulate a clinical trial in which individuals are randomized at
baseline and then followed for for a fixed amount of time, at which point mortality status
and, for those remaining alive, CD4 cell count are ascertained. Hence the utility function for
our comparison involves both mortality and CD4 count among survivors.
In addition to the usual complication of time-varying confounding caused by treatment not
being randomly allocated, the structure of the dataset poses three specific challenges that
we address here. First, unlike with many published analyses comparing dynamic treatment
regimes, treatment initiation is measured in continuous time; second, the outcome of interest,
CD4, is measured infrequently and at irregularly spaced time intervals, leading to incomplete
data at the target measurement time; third, some individuals may not complete follow up,
leading to censoring of both death time and CD4 count.
We use inverse probability weighting (IPW) to handle confounding, and imputation to
address missingness due to sparse measurement and censoring. To deal with continuous-
time measurement of treatment initiation, we derive continuous-time versions of the relevant
probability weights. To deal with missingness, we rely on imputations from a model of the
joint distribution of CD4 count and mortality fitted to the observed data. We take a two-step
approach: first, the joint model is fitted to the observed data and used to generate (multiple)
3imputations of missing CD4 and mortality outcomes; second, we apply IPW to the filled-in
datasets to generate causal comparisons between different DTR.
1.2 Comparing dynamic treatment regimes using observational data
Randomized controlled trials can be used to evaluate a DTR of the form described above.
(see Violari et al., 2008 for example). Observational data afford large sample sizes and rich
information on treatment decisions, but the lack of randomization motivates the need to
use specialized methods for drawing valid causal comparisons between regimes. Statistical
methods for drawing causal inferences about DTR from observational data include the g-
computation algorithm (Robins, 1986), inverse probability weighted estimation of marginal
structural models (Robins et al., 2008), and g-estimation of structural nested models (Moodie
et al., 2007); see Daniel et al. (2013) for a comprehensive review and comparison.
The g-computation formula was first introduced by Robins (1986) and has been used
to deal with time-dependent confounding when estimating the causal effect of a time-
varying treatment. The unobserved potential outcomes and intermediate outcomes that
would have been observed under different hypothetical treatments are predicted from models
for potential outcomes and models for time-varying confounders. The predicted potential
outcomes under different hypothetical DTR assignments are then contrasted for causal
effect estimates. As the number of longitudinal time points increase, the method more
heavily leverages parametric modeling assumptions used for extrapolation of covariates and
outcomes, increasing the reliance on these assumptions and introducing potential for bias
from model mis-specification.
The IPW approach re-weights each individual inversely by the probability of following
specific regimes so that, in the weighted population, treatment can be regarded as randomly
allocated to these regimes. Time-varying weights are required for handling time-dependent
confounding. This involves specifying a model for treatment trajectory over longitudinal
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follow-up that can include time-dependent covariates. The IPW approach does not require
models for the distribution of outcomes and covariates, which in principle makes it less
susceptible to model misspecification than the g-computation formula. The method can
however generate unstable parameter estimates if there are extreme weights, raising the
possibility of finite-sample bias, which can often be alleviated by using stabilized weights or
truncation (Cole and Herna´n, 2008; Cain et al., 2010).
1.3 IeDEA data
The IeDEA consortium, established in 2005, collects clinical and demographic data on HIV-
infected individuals from seven global regions, four of which are in Africa. Data from African
regions derive from 183 clinics providing ART (Egger et al., 2012). Our analysis makes use of
clinical encounter data, drawn from the East Africa region, on 1962 HIV-infected and ART
naive adolescents who were diagnosed with HIV between February 20, 2002 and November
19, 2012. The dataset contains individual-level information at diagnosis on the following
variables: age, gender, clinic site, CDC class (a 4-level ordinal diagnostic indicator of HIV
severity), CD4 count, weight-for-age Z scores (WAZ) and height-for-age Z scores (HAZ).
The dataset also includes longitudinal information on ART initiation status, death, CD4
count, WAZ and HAZ. These data were generated before the 2015 WHO guidelines that
recommend immediate ART initiation, which yields significant variability in ART initiation
patterns observed in our data. The follow-up visits vary considerably from patient to patient,
resulting in irregularly and sparsely measured CD4 cell count (1.71, 1.32, 1.10 per person
per year within one, two and three years of diagnosis) and various ART initiation patterns
(Figure 1). Kaplan-Meier estimates of mortality one-, two- and three-years post diagnosis
are 3.3%, 4.5% and 5.6% respectively.
Our goal is to compare CD4 cell count and mortality rate at one and two years post
enrollment under dynamic regimes defined in terms of initiating treatment at specific CD4
5threshold values. In the next section we define the randomized trial our analysis is designed
to emulate, and the outcome measure (utility) used for the comparisons.
The remainder of the paper is organized as follows: Section 2 describes notation and
the statistical problem. Section 3 delineates the approaches to estimating and comparing
dynamic continuous-time treatment initiation rules with sparsely measured outcomes and
death. Section 4 presents results from our analysis of IeDEA data and highlights new insights
relative to previous studies. Section 5 provides a summary and directions for future research.
2. Notation and dynamic regimes
2.1 Randomized trial being emulated to compare dynamic regimes
Ideally, causal comparisons of dynamic regimes should be based on a hypothetical randomized
trial (Herna´n et al., 2006). In our setting, the trial we are emulating would randomize
individuals at time t = 0 to regimes in a set Q = {0, 200, 210, 220, . . . , 490, 500,∞}, where
q = 0 corresponds to ‘never treat’ and q =∞ denotes ‘treat immediately’, and other regimes
correspond to initiating treatment when CD4 falls below q. Each individual would be followed
to a specific time point t∗, at which point survival status would be ascertained and, for those
surviving to t∗, CD4 would be measured. For those who discontinue follow up prior to t∗, we
assume treatment status (on or off) at the time of discontinuation would still apply at t∗.
For each individual, let {Dq : q ∈ Q} represent the set of potential outcomes, one for
each regime, indicating death at t∗, such that Dq = 1 if dead and Dq = 0 if alive. Similarly
define {Yq : q ∈ Q} to be the set of potential CD4 counts for an individual who survives
to t∗. Now define, for q ∈ Q, the composite outcome Xq = (1 − Dq)Yq, with Xq = 0 for
those who die prior to t∗ and Xq = Yq > 0 for those who survive. We use both mortality
rate P (Dq = 1) = P (Xq = 0) and quantiles of Xq as a basis for comparing treatments.
The cumulative distribution function (CDF) of Xq is a useful measure of treatment utility
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because it has point mass at zero corresponding to the mortality rate, and thereby reflects
information about both mortality and CD4 cell count among survivors; e.g., P (Xq > 0) is
the survival fraction and P (Xq > x), for x > 0, is proportion of individuals who survive to
t∗ and have CD4 count greater than x.
2.2 Defining dynamic treatment regime
Let {Z(t) : t > 0}, where Z(t) > 0, represent CD4 cell count, which is defined for all t but
measured only at discrete time points for each individual (see below). Let T denote survival
time, with {NT (t) : t > 0} its associated zero-one counting process. Each individual has a
p×1 covariate process {L(t) : t > 0}, some elements of which may be time varying. The time-
varying covariates may be recorded at times other than those where Z is recorded. Finally let
A denote the time of treatment initiation, with associated counting process {NA(t) : t > 0}
and intensity function λA(t). Adopting a convention in the DTR literature (Robins et al.,
2008), we assume the decision to initiate ART at t is made after observing the covariates
and CD4 cell count; that is, for a given t, NA(t) occurs after Z(t) and L(t). Finally let C be
a censoring (dropout) time, with associated counting process NC(t).
At a fixed time t, let H(t) = {Z(t), NT (t), L(t), NA(t), NC(t)} represent the most recent
values of each process. We use overbar notation to denote the history of a process, so that
(e.g.) L(t) = {L(s) : 0 6 s 6 t} is the history of L(t) up to t. All individuals are observed
at baseline and then at a discrete number of time points whose number, frequency and
spacing may vary. Hence the observed-data process for individual i (= 1, . . . , n) is denoted
by H i(tiKi) = {Hi(t) : t = 0, ti1, ti2, . . . , tiKi}.
2.3 Mapping observed treatment to dynamic treatment regime
The dynamic treatment regime ‘initiate treatment when Z(tj) falls below threshold q’ (where
tj is time at the jth visit) is a deterministic function rq(H(tj)) that depends on observed
values of Z(tj) and treatment history N
A
(tj); for brevity we suppress subscript j and write
7rq(t), which applies to each individual’s actual visit times. As some patients have missing
baseline CD4, let RZ(t) be a binary indicator with RZ(t) = 1 denoting that CD4 has not
been observed by time t. At t = 0, the rule is rq(0) = I{RZ(0) = 1 or Z(0) < q}, indicating
immediate initiation regardless of Z(0) or treat if Z(0) is below q. For t > 0, we define
Zmin(t) = minj:06tj<t Z(tj) to be the lowest previously recorded value of Z prior to t. Then,
rq(t) =

0 if {NA(t−) = 0 and Zmin(t) > q and Z(t) > q} or RZ(t) = 1,
1 if NA(t−) = 0 and Zmin(t) > q and Z(t) < q,
1 if NA(t−) = 1.
In words, the first line of the rule says not to treat if an individual has not yet initiated
treatment and Z(t) has not fallen below q or has not been observed; the second line says to
treat if time t represents the first time Z(t) has fallen below q; the third line says to keep
treating once ART has been initiated.
In addition to the observed data process, we define a regime-specific compliance process
{∆q(t) : t > 0} where ∆q(t) = 1 if regime q is being followed at time t and ∆q = 0 otherwise.
Written in terms of H(t) and rq(t), we have ∆q(t) = N
A(t)rq(t) + {1 − NA(t)}{1 − rq(t)}.
Hence if an individual’s actual treatment status at time t agrees with the DTR q, then this
individual is compliant with regime q at time t. Thus for each individual and for each q ∈ Q,
we observe, in addition to H(t), a regime compliance process {∆qi(t) : t = 0, ti1, . . . , tiKi}.
2.4 Missing outcomes due to sparse measurement times and censoring
For those who remain alive at t∗, the observed Xi corresponds to Zi(t∗). When measurement
of Zi(t) is sparse and irregular, Zi(t
∗) will not be directly observed unless tik = t∗ for some
k ∈ {1, . . . , Ki}. In settings like this, it is common to define the observed outcome as the
value of Zi(t) closest to t
∗ and falling within a pre-specified interval [ta, tb] containing t∗.
Specifically, Xi is the value of Z(tik) such that tik ∈ [ta, tb] and |tik− t∗| is minimized over k.
Even using this definition, the interval [ta, tb] still may not contain any of the measurement
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times for some individuals; hence Xi can be missing even for those who remain in follow up
at t∗. The other cause of missingness in Xi is dropout, which occurs when tiKi < ta.
For both of these situations, we rely on multiple imputation based on a model for the joint
distribution of the CD4 process Z(t) and the mortality process NT (t). The general strategy
is as follows: first, we specify and fit a model for the joint distribution [Z(t), NT (t) |H(t)]
of CD4 and mortality, conditional on observed history. For those who are known to be alive
but do not have a CD4 measurement within the pre-specified interval [ta, tb], we impute
X˜i ∼ [Z(t∗) |H i(t∗)] from the fitted CD4 submodel. For those who are missing Xi because of
right censoring, we proceed as follows: (i) calculate P{NT (t∗) = 1 |H i(tiKi)} from the fitted
survival submodel, and impute D˜i from a Bernoulli distribution having this probability;
(ii) for those with D˜i = 0, impute X˜i ∼ [Z(t∗) |H i(t∗)] from the fitted CD4 submodel;
(iii) for those with D˜i = 1, set X˜i = 0. Further details are given in Section 3.5.
3. Estimating and comparing effectiveness of dynamic regimes
3.1 Assumptions needed for inference about dynamic regimes
We are interested in parameters or functionals of the potential outcomes distribution FXq(x) =
P (Xq 6 x). Specific quantities of interest are the mortality rate θq1 = P (Xq = 0) = FXq(0),
the median of the distribution of the composite outcome θq2 = F
−1
Xq
(1
2
), and the mean CD4
count among survivors θq3 = E(Xq |Xq > 0). We first consider inference in the case where
there is no missingness in the observable outcomes Xi. Estimates for each of these quantities
can be obtained using weighted estimating equations under specific assumptions.
A1. Consistency assumption. To connect observed data to potential outcomes, we use the
consistency relation Xi = Xqi when ∆qi(t
∗) = 1, for all q ∈ Q, which implies that the
observed outcome Xi corresponds to the potential outcome Xqi when individual i actually
9follows regime q. Note that an individual can potentially follow more than one regime at any
given time.
A2. Exchangeability assumption. In observational studies, individuals are not randomly
assigned to follow regimes. Decisions on when to start ART are often made by based on
guidelines and observable patient characteristics. We make the following exchangeability
assumption, also known as sequential randomization of treatment: λA(t |H(t), T > t,Xq) =
λA(t |H(t), T > t), for t < t∗. This assumption states that initiation of treatment at t among
those who are still alive is conditionally independent of the potential outcomes Xq conditional
on observed history H(t).
A3. Positivity assumption. Finally we assume that at any given time t, there is positive
probability of initiating treatment, among those who have not yet initiated, for all configu-
rations H(t) (Robins et al., 2008): P
{
λA(t |H(t), T > t) > 0} = 1. This implicitly assumes
a positive probability of visiting clinic in the interval [t, t∗], conditional on H(t).
3.2 Weighted estimating equations for comparing specific regimes
For illustration, consider estimating the mortality rate θq1 = P (Xq = 0). If individuals
are randomized to specific regimes, a consistent estimator of the death rate is the sample
proportion among those who follow regime q; i.e., θ̂q1 =
∑
i ∆qi(t
∗)I(Xi = 0) /
∑
i ∆qi(t
∗) .
This estimator is the solution to
∑
i ∆qi(t
∗){I(Xi = 0)− θq1} = 0, which is an unbiased esti-
mating equation when θq1 = θ
∗
q1 is the true value of θq1. We can similarly construct unbiased
estimating equations for other quantities of interest. For example, under randomization, a
consistent estimator of the median of Xq is the solution to
∑
i ∆qi(t
∗)
{
I(Xi 6 θq2)− 12
}
= 0.
For observational data, relying on the assumptions of consistency, positivity and exchange-
ability, we can obtain consistent estimates of quantities of interest using weighted estimating
equations. Returning to mortality rate, a consistent estimator of θq1 can be obtained as the
solution to the weighted estimating equation
∑n
i=1 ∆qi(t
∗)Wqi {I(Xi = 0)− θq1} = 0, where
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Wqi = 1/P{∆q(t∗) = 1 |H i(t∗)} is the inverse probability of following regime q through
time t∗ (Robins et al., 2008; Cain et al., 2010; Shen et al., 2017).
In practice the weights Wqi must be estimated from data; some of the estimated weights
can be large, leading to estimators with high variability (Cain et al., 2010). This problem
can be ameliorated to some degree by using stabilized weights of the form
W sqi =
P {∆q(t∗) = 1}
P
{
∆q(t∗) = 1 |H i(t∗)
} . (1)
In this case, the numerator of the weight function needs to be calculated directly from
the regime indicator processes. Specifically, for each regime q, define a 0-1 counting process
N q(t) = 1−∆q(t) that jumps when regime q is no longer being followed, and let Λq(t) denote
its associated cumulative hazard function. Then Sq(t) = P{N q(t) = 0} = P{∆q(t) = 1};
hence (an estimate of) Sq(t∗) = exp{−Λq(t∗)} can be used as the numerator weight.
3.3 Comparing regimes along a continuum
We can examine the effect of DTR q on Xq at a higher resolution along a continuum such as
Q = {200, 210, . . . , 500} (we use integers for Q, but theoretically it can include continuous
values). When the number of regimes to be compared is large, it is highly possible that not
every regime is followed by a sufficiently large number of individuals, and sampling variability
associated with the regime effect estimated using the procedure for discrete regimes may be
large (Herna´n et al., 2006). A statistically more efficient approach is to formulate a causal
model that captures the smoothed effect of q on a parameter of interest; we illustrate using
the median θq2 = F
−1
Xq
(1
2
).
Let ql and qu denote the lower and upper bound of the regime continuum. Assume F
−1
Xq
(τ),
where τ is a fixed quantile, follows a structural model
F−1Xq (τ) = α0I(q =∞) + α1I(q = 0) + I(q ∈ [ql, qu])d(q), (2)
where d(·) is an unspecified function with smoothness constraints. In our application, we use
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natural cubic splines constructed from piecewise third-order polynomials that pass through
a set of control points, or knots, placed at quantiles of q. This allows d(q) to flexibly capture
the effect of q along the continuum and enables separate estimation of the discrete regimes
q = ∞ and q = 0. Parameterizing our model in terms of the basis functions of a natural
cubic spline with J knots (Hastie et al., 2009) yields F−1Xq (τ) = α
>V (q), where
V (q)(J+2)×1 = [I(q =∞), I(q = 0), I(q ∈ [ql, qu])d†(q)>]>
and d†(q) = [d†1(q), · · · , d†J(q)]> are the J basis functions of d(q). The parameter α is a vector
of J+2 coefficients for I(q =∞), I(q = 0) and the basis functions d†(q). The causal effect of
regime q on the potential outcome Xq is therefore encoded in the parameter α. A consistent
estimator of α can be obtained by solving the estimating equation (Leng and Zhang, 2014):∑
i
∆qi(t)W
s
qiVi(q)
[
I{Xi − V >i (q)α > 0} − τ
]
= 0.
Setting τ = 0.5 estimates the causal effect of q on the median of Xq.
3.4 Derivation and estimation of continuous time weights
3.4.1 Assuming no dropout or death prior to t∗. The denominator of W sqi in equation (1)
is the probability of individual i following regime q through t∗, conditional on observed history
Hi(t
∗). As described in Robins et al. (2008); Cain et al. (2010) and Shen et al. (2017), for
discrete-time settings where the measurement times are common across individuals, this
probability corresponds to the cumulative product of conditional probabilities of treatment
indicators over a set of time intervals 0 = t0 < t2 < · · · < tK = t∗. Specifically,
P
{
∆qi(t
∗) = 1
∣∣ H i(t∗)} = K∏
k=0
P
(
∆qi(tk) = 1
∣∣ H i(tk))
=
K∏
k=0
P
[{
NAi (tk)rqi(tk) + (1−NAi (tk))(1− rqi(tk))
}
= 1
∣∣H i(tk)]
=
K∏
k=0
{
P
(
NAi (tk) = 1
∣∣H i(tk)) I (rqi(tk) = 1)
+ P
(
NAi (tk) = 0
∣∣H i(tk)) I (rqi(tk) = 0)} . (3)
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This establishes the connection between regime compliance and treatment history. Equa-
tion (3) represents the treatment history among those with ∆qi(t
∗) = 1; therefore, to compute
the probability of regime compliance for those with ∆qi(t
∗) = 1, we just need to model their
observed treatment initiation process, as described in equation (4) below.
This observation allows us to generalize the weights for the discrete time setting to the
continuous time process. Let dNAi (t) be the increment of N
A
i over the small time interval
[t, t+dt). Note that conditional on H(t), the occurrence of treatment initiation for individual
i in [t, t + dt) is a Bernoulli trial with outcomes dNAi (t) = 1 and dN
A
i (t) = 0. Equation (3)
can therefore be written
K∏
k=0
P
(
dNAi (t) = 1 |H i(t)
)dNi(t)
P
(
dNAi (t) = 0 |H i(t)
)1−dNi(t)
, (4)
which takes the form of the individual partial likelihood for the counting process {NAi (t) :
0 6 t 6 t∗}. When the number of time intervals between t0 and tK increases, dt becomes
smaller, and the finite product in (4) will approach a product-integral (Aalen et al., 2008)
R
06t6t∗
{
λA(t |H i(t))dt
}dNAi (t) {1− λA(t |H i(t))dt}1−dNAi (t) (5)
=
[ ∏
06t6t∗
{
λA(t |H i(t))
}∆NAi (t)] exp{−∫ t∗
0
λA(t |H i(t))dt
}
, (6)
where ∆NAi (t) = N
A
i (t)−NAi (t−). The product integral of the first part in (5) is the finite
product over the jump times of the counting process, hence the first factor in (6). The second
factor in (6) follows from properties of the product-integral of an absolutely continuous
function (Aalen et al. 2008, Appendix A.1).
The individual counting process {NAi (t), 0 6 t 6 t∗} will have at most one jump (at Ai),
and in our case patients stay on ART once it is initiated. Hence the product integral only
needs to be evaluated up to the ART initiation time. Equation (6) therefore reduces to
P
{
∆qi(t
∗) = 1 |H i(t∗)
}
= λA(Ai |H(Ai))SA(Ai |H i(Ai))Ni(t∗) + SA(t∗ |H i(t∗)){1−Ni(t∗)}
= fA(Ai |H i(Ai))NAi (t∗) + SA(t∗ |H i(t∗)){1−NAi (t∗)}, (7)
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where SA(t |H(t)) = exp{−ΛA(t |H(t))} is the survivor function associated with the ART
initiation process.
For an alternate derivation of the continuous time weights, see Johnson and Tsiatis (2005),
who use a Radon-Nikodym derivative of one integrated intensity process (under randomized
treatment allocation) with respect to another (for the observational study), and arrive at
the same weighting scheme as ours. Simulation studies by Hu et al. (2018) demonstrate
consistency and stability of weighted estimators using continuous-time weights in empirical
settings when assumptions A1-A3 hold and the weight model is correctly specified.
Components of the denominator weights are estimated from a fitted hazard model for
treatment initiation. Specifically we assume λA(t |H(t)) follows a Cox proportional hazards
model λA(t |H(t)) = λA0 (t)u(H(t);φ), where u is a strictly positive function capturing the
effect of covariates and φ is a finite-dimensional parameter vector. Details of the model
specification used in our application are given in Section 4. The parameter φ is estimated
using maximum partial likelihood estimation, and the baseline hazard function λA0 (t) is
estimated using the Nelson-Aalen estimator. The functions fA and SA are estimated via
ŜA(t |H(t)) = exp
{
−
∫ t
0
u(H(s); φ̂) dΛ̂A0 (s)
}
, (8)
f̂A(t |H(t)) = dΛ̂A(t |H(t)) ŜA(t |H(t)). (9)
To estimate the stabilizing numerator weight P {∆q(t∗) = 1}, we use the q-specific survivor
function associated with the counting process N q(t), estimated using the Nelson-Aalen
estimator Ŝq(t∗) = exp{−Λ̂q(t∗)}.
3.4.2 Considering dropout or death prior to t∗. In the IeDEA data, some participants
drop out prior to t∗, which requires modifications to the weight specification. We make an
additional assumption:
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A4. Conditional constancy assumption. Once lost to follow up at Ci < t
∗, treatment and
regime status remain constant; i.e., NA(t) = NA(Ci) and ∆qi(t) = ∆qi(Ci) for all t ∈ [Ci, t∗].
Under this assumption, both regime adherence and treatment initiation status are deter-
ministic after Ci. Hence the stabilized weight is S
q(Ci)/f
A(Ai |H(Ai)) for those who initiated
treatment prior to Ci and S
q(Ci)/S
A(Ci |H(Ci)) for those who have not. If death occurs at
Ti < t
∗, both compliance and treatment initiation processes only need to be evaluated up
to time Ti, and estimation of the stabilized weights is same as described above, with Ti
replacing Ci. Let Ui = min(Ti, Ci, t
∗) denote duration of follow up time for individual i. The
modified stabilized weight can be written as
W sqi =
Sq(Ui)I(Ui < t
∗) + Sq(t∗)I(Ui > t∗)
fA(Ai |H(Ai))
NAi (t
∗)
+
{
Sq(Ui)
SA(Ui |H i(Ui))
I(Ui < t
∗) +
Sq(t∗)
SA(t∗ |H i(t∗))
I(Ui > t∗)
}(
1−NAi (t∗)
)
. (10)
Estimation follows by equations (8) and (9).
3.5 Imputation strategy for missing and censored outcomes
Imputation of missing CD4 counts and mortality status are generated from a joint model
of CD4 and survival. The two processes are linked via subject-specific random effects that
characterize the true CD4 trajectory (Rizopoulos, 2012). Hazard of mortality is assumed to
depend on the true, underlying CD4 count as described below.
Observed CD4 counts as a function of time are specified with a two-level model. At the
first level, Zi(t) = mi(t) + ei(t), where mi(t) is the true, underlying CD4 cell count and
ei ∼ N(0, σ(t)) is within-subject variation of the observed counts around the truth. The
second level specifies the trajectory in terms of baseline covariates Li(0), treatment initiation
time Ai, follow up time t, and subject-specific random effects bi,
mi(t) = h1(Li(0), N
A
i (t), t; β) + h2(N
A
i (t), t; bi).
In the model for mi(t), h1(Li(0), Ai, t; β) models the effect of L(0), A and t in terms of a
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population-level parameter β and h2(Ai, t; bi) captures individual-specific time trajectories
relative to treatment initiation in terms of random effects bi, where where bi ∼ N(0,Ω).
The hazard model for death uses true CD4 count mi(t) as a covariate, in addition to
components of Li(0) and treatment timing. The specification we use in our analysis is
log λT (t |mi(t), Li(0), Ai(t)) = log λT0 (t) + g1(mi(t); γ1) + g2(Li(0), NAi (t); γ2) (11)
where λT0 (t) is an unspecified baseline hazard function, g1(·; γ1) is a smooth, twice-differentiable
function indexed by a finite-dimensional parameter γ1; and g2(·; γ2) captures the main
effect of baseline covariates, the instantaneous effect of treatment initiation, and potential
interactions between them. In our application, we use cubic smoothing splines to model the
effects of mi(t) and of continuous baseline covariates. This model has fewer covariates than
the CD4 model because of relatively low mortality rates.
The joint model is used to generate imputations where CD4 count and mortality informa-
tion are missing at time t∗. The variance of our target parameters θq = (θq1, θq2, θq3) is based
on Rubin’s variance estimator (Rubin, 1987); full details of model specifications and variance
calculations used in the data analysis in Section 4 appear in Supporting Information.
4. Application to IeDEA data
Our analysis uses longitudinal data on 1962 adolescents with at least two years of follow up
time. Time is measured in days. We evaluate effectiveness of the regimes at times t∗ = 365
and t∗ = 730 days (one and two years, respectively) after diagnosis. To capture the CD4
observed at t∗, we set [ta, tb] = [t∗ − 180, t∗ + 180]; hence Y is the CD4 count measured at
a time falling within [ta, tb] and closest to t
∗. If no CD4 is captured within [ta, tb], then Y is
missing. The percentage of missing data for Y is 29.1% at one year and 43.4% at two years.
Among those with missing one-year outcome, 41.2% were lost to follow up prior to ta; for
those with missing two-year outcome the proportion is 42.5%. Table 1 describes summary
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statistics for baseline variables and follow up, the observed outcome pair (Y,D) (CD4 and
deaths), and ART initiation.
Missing outcomes are imputed following the strategies described in Section 3.5, and the
complete datasets are analyzed using IPW methods for the causal comparative analysis. The
fit of the CD4 submodel was examined using residual plots and examination of individual-
specific fitted curves; for the mortality submodel we tested the proportional hazards assump-
tion for each term included in the model. These model checks indicated no evidence of lack
of fit. Details appear in Supporting Information.
Following the deterministic rule rq(H(t)) described in Section 3, we create the regime-
specific indicators ∆qi(t
∗) for q ∈ Q for each patient based on the concordance between their
ART initiation history {NA(t) : 0 6 t 6 t∗} and rq(H(t∗)). To estimate regime weights, we
fit the model λA(t |H(t)) = λA0 (t)u(H(t);φ) to individuals’ treatment and covariate histories
observed in the original data to estimate the denominator of W sqi in (1). For the time-varying
component of H(t), we include the most recently observed values of CD4, WAZ and HAZ as
main effects, modeled using cubic splines. For baseline covariates, we include age at diagnosis
(modeled using a cubic spline) and the categorical variables gender and CDC symptom
classification (mild, moderate, severe, asymptomatic, missing). To estimate the numerator
of the stabilized weights, we use the Nelson-Aalen estimator of the survival function for
each regime-specific compliance process, as described in Section 3.4.1. We truncated the
weights at 5% and 95% quantiles to improve stability. We conducted a sensitivity analysis
to assess the impact of weight truncation. The point estimates and the confidence intervals
for treatment effect on mortality were unchanged with different weighting schemes. Point
estimates and variation associated with treatment effect on the composite outcome increased
with less truncation; the confidence intervals indicated greater variability but no change in
substantive conclusion about treatment effect. For the denominator weight model, we tested
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the proportional hazards assumption for each term included in the model and found no
violations of the assumption. Details appear in Supporting Information.
We summarize the comparative effectiveness for specific regimes q ∈ {0, 200, 350, 500,∞}
in Table 2 in terms of mortality proportion θq1 = P (Xq = 0), median of the distribution
of the composite outcome θq2 = F
−1
Xq
(1
2
), and mean CD4 count among survivors, θq3 =
E(Xq |Xq > 0). (The quantity θq3 is not a causal effect because it conditions on having
survived to time t∗.) Confidence intervals are constructed using the normal approximation
to the sampling distribution, derived from bootstrap resampling, as described in Supporting
Information.
Immediate ART initiation yields significantly lower mortality rate and higher medians of
the composite outcome at both years than delayed initiation. The “never treat” regime leads
to significantly higher mortality rate; among the patients who survive to one year, CD4
is higher – resulting in higher θq2 and θq3 – indicating that those who do survive without
treatment may be relatively healthier at the beginning of the follow up.
Figure 2 shows the effect of weighting on estimated medians ofXq for q = 0, 200, 350, 500,∞.
We compare weighted and unweighted estimates using imputed data; the weighted estimates
suggest immediate ART initiation leads to highest θ̂q2, whereas the unweighted estimates
ignoring nonrandom allocation of DTRs recommend ‘never treat’ to be the optimal regime.
The difference could be attributable to differences in baseline covariates (see Table 8 in
Supporting Information). Not surprisingly, the weighted estimates have higher variability.
Finally, we estimate the causal effect of the DTR on the median of Xq using the smoothed
relationship between F−1Xq (
1
2
) and q from model (2). The estimated “dose response” curves of
θ̂q2 versus q appear in the top panel of Figure 3. The bottom panel describes the difference
in θ̂q2 between dynamic regimes q = ∞ and q ∈ {0, 200, 210, . . . , 500}. Our results indicate
that immediate ART initiation leads to significantly higher median values of the composite
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outcome Xq than delayed ART initiation. Furthermore, as an illustration of increased effi-
ciency, the variance of the one-year outcome associated with q = 350 estimated from the
structural model is 180, compared to 209 for the regime-specific estimate, a 13.9% reduction.
The R code used to implement our approaches is available in Supporting Information.
5. Summary and discussion
Motivated by inconclusive evidence for supporting the current WHO guidelines promoting
immediate ART initiation in adolescents, we have conducted an analysis comparing dynamic
treatment initiation rules. Our approach utilizes the theory of causal inference for DTRs. We
extend the framework to allow the causal comparisons of both specific regimes and regimes
along a continuum, Additionally, propose strategies to address sparse outcomes and death,
and use a composite outcome that can be used to draw causal comparisons between DTRs.
Our analysis suggests that immediate ART initiation leads to mortality benefit and higher
median values of the composite outcome, relative to delayed ART initiation. The ‘never
treat’ regime yields significantly higher mortality than other initiation rules.
The data from IeDEA pose several challenges that we addressed within our analysis. First,
treatment initiation times are recorded on a continuous time scale. Existing approaches have
relied primarily on discretization of the time axis to construct inverse probability weights.
We have derived a method to construct weights that uses the continuous time information.
Similar strategies have been employed in Hu et al. (2018) and Johnson and Tsiatis (2005);
see also Lok (2008) for related work in the context of structural nested mean models.
Second, CD4 counts are measured at irregularly spaced times. This creates challenges when
the goal is to compare treatment regimes at a specific follow up time, as would be the case
with a randomized trial. Moreover, even though our sample comprises those who would be
scheduled to have at least two years of follow up, some individuals discontinue follow up
prior to that time. These features of the data lead to incomplete observation of CD4 count
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at the target analysis time and to censoring of death times. To address this issue we have
relied on a parametric model for the joint distribution of observed CD4 counts and death
times. The CD4 submodel is flexible enough to capture important features of the longitudinal
trajectory of CD4 counts, and is used to impute missing observations at the target follow up
time. The mortality submodel, which depends explicitly on the CD4 trajectory, is used to
impute mortality status at the target estimation time. A limitation of the imputation model
is that death and CD4 may depend on HIV viral load, but availability of this variable is
limited in our data and therefore not included in the model.
The primary strength of this approach is its ability to handle a complex data set on its own
terms, without artificially aligning measurement times. Although imputation-based analyses
rely on extrapolating missing outcomes, and both the weight model and imputation model
must be correctly specified, a potential advantage of our approach over g-computation is
reduced dependence on data extrapolation. There are several possible extensions as well.
First, largely due to limitations related to computing, we used a two-step approach to fit our
observed-data imputation model rather than a joint likelihood approach. There may be some
small biases (Rizopoulos, 2012) introduced by using a two-step rather than fully joint model.
Second, the imputation model may not be fully compatible with the weighting model in the
sense that we are not constructing a joint distribution of all observed data. Our approach
emulates a setting whereby the data imputer and the data analyst are separate: the imputed
dataset can be turned over for whatever kind of analysis would be applied to a complete
dataset. Empirical checks to our joint model for CD4 and mortality showed no evidence of
lack of fit to the observed data (see Supporting Information). To make the models more
flexible, it may be possible to employ machine learning methods as in Shen et al. (2017).
Finally, developing sensitivity analyses to capture the effects of unmeasured confounding for
our model would be a worthwhile and important contribution.
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Figure 1. CD4 and ART initiation status during follow up for 9 randomly selected
individuals. Empty circles indicate no ART and filled circles represent on ART. Two gray
lines denote one year and two years post diagnosis. Purple line corresponds to end of follow
up.
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Figure 2. Comparing the median values of Xq under regime q ∈ {0, 200, 350, 500,∞}.
Weighted (W) and unweighted (UW) estimates are compared side-by-side.
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Figure 3. The effectiveness of continuous regimes. The upper panel presents the median
of Xq, θ̂q2, at one-year and two-years; the bottom panel displays the difference in θ̂q2 at
one-year and two-years between regimes q =∞ and q ∈ {0, 200, 210, . . . , 500}. The triangles
represent θ̂q2 corresponding to regime q = 0 (upper panel), and the difference in θ̂q2 between
regimes q = ∞ and q = 0 (bottom panel). Similarly, the diamonds correspond to θ̂q2 under
regime q =∞. The filled symbols are the mean values, and the empty symbols are the upper
and lower bounds of the 95% confidence intervals.
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Table 1
Summary statistics
n = 1962
at t∗ = 1 year at t∗ = 2 years
ART initiated 1286 (65.5%) 1422 (72.5%)
death 61 (3.1%) 80 (4.1%)
CD4 counts per person 1.71 2.64
Mean (SD) or Count (%) % missing
CD4 343.05 (314.78) 21.3%
WAZ −2.64 (1.83) 33.7%
HAZ −2.10 (1.48) 36.1%
age 12.21 (1.41) 0
male 863 (44.0%) 0
CDC class 71.6%
mild 200 (10.2%)
moderate 73 (3.7%)
severe 88 (4.5%)
asymptomatic 196 (10.0%)
person time follow up* 3.6 (1.7, 6.1)
∗median (1st, 3rd quartile) in years
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Table 2
Comparing effectiveness of specific regimes q ∈ {0, 200, 350, 500,∞} for t∗ = 1 year and t∗ = 2 years.
θq1 = P (Xq = 0) = FXq (0), θq2 = F
−1
Xq
( 1
2
), θq3 = E(Xq |Xq > 0). 95% confidence intervals are shown below the
point estimates.
0 200 350 500 ∞ ∞ vs. 500
t∗ = 1
θ̂q1 .050 .018 .017 .020 .012 −.008
(.032, .078) (.007, .044) (.008, .038) (.009, .040) (.006, .024) (−.015,−.001)
θ̂q2 381 292 354 375 416 41
(345, 418) (260, 324) (320, 387) (350, 401) (381, 451) (12, 70)
θ̂q3 416 326 377 401 466
(380, 453) (294, 357) (349, 406) (373, 429) (435, 498)
t∗ = 2
θ̂q1 .076 .040 .033 .036 .023 −.013
(014, .037) (.050, .110) (.021, .074) (.019, .059) (.021, .060) (−.023,−.004)
θ̂q2 353 303 358 387 438 51
(304, 402) (262, 343) (310, 407) (341, 434) (395, 481) (14, 87)
θ̂q3 394 345 388 418 484
(348, 441) (308, 382) (352, 423) (381, 455) (447, 522)
